Get the Stockscreener App
16.75
4.56%
-0.80
Pre-market:
17.98
1.23
+7.34%
Rapport Therapeutics Inc Stock (RAPP) Latest News
Rapport Therapeutics (NASDAQ:RAPP) Short Interest Down 15.3% in January - MarketBeat
JPMorgan Chase & Co. Purchases Shares of 4,033 Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Trading Up 4.6%Here's What Happened - MarketBeat
J&J-backed Rapport Therapeutics files for $100M IPO - MSN
Rapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
(RAPP) Proactive Strategies - Stock Traders Daily
Rapport Therapeutics (RAPP) Projected to Post Quarterly Earnings on Thursday - Defense World
Barclays PLC Increases Stock Holdings in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap UpTime to Buy? - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Reaches New 12-Month LowWhat's Next? - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap DownWhat's Next? - MarketBeat
Rapport Therapeutics Announces Positive Results from PET and MAD-2 Trials for RAP-219On January 9, 2025, Rapport Therapeutics, Inc. (NASDAQ: RAPP) disclosed the outcomes from its positron emission tomography (PET) trial and the second multiple as - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6.9%What's Next? - MarketBeat
(RAPP) Technical Data - Stock Traders Daily
Rapport Therapeutics announces new Phase 1 data for RAP-219 - Yahoo Finance
CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - The Manila Times
CORRECTION -- Rapport Therapeutics Announces New Phase 1 - GlobeNewswire
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - The Manila Times
Rapport Therapeutics Announces New Phase 1 Data, Further - GlobeNewswire
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - GlobeNewswire Inc.
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's ... - The Bakersfield Californian
Rapport Therapeutics (NASDAQ:RAPP) Sets New 52-Week LowHere's What Happened - MarketBeat
Geode Capital Management LLC Makes New $4.13 Million Investment in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Geode Capital Management LLC Purchases New Shares in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Barclays PLC Has $264,000 Stock Holdings in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
State Street Corp Invests $1.19 Million in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
58,046 Shares in Rapport Therapeutics (NASDAQ:RAPP) Purchased by State Street Corp - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 4%Here's Why - MarketBeat
Learn to Evaluate (RAPP) using the Charts - Stock Traders Daily
TARPγ8 negative allosteric modulators as new approach for epilepsy - BioWorld Online
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13 - Business Wire
Shareholder Alert: Ademi LLP investigates whether Nordstrom, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire
When (RAPP) Moves Investors should Listen - Stock Traders Daily
1,684 Shares in Rapport Therapeutics (NASDAQ:RAPP) Bought by BNP Paribas Financial Markets - Defense World
LTRPA, LTRPB Investors Have the Opportunity to Join Investigation of Liberty TripAdvisor Holdings, Inc. with the Schall Law Firm - Business Wire
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 - Business Wire
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 4.6%Should You Sell? - MarketBeat
The Manitowoc Company reaches agreement to settle U.S. EPA matter regarding its emissions certification and compliance process - Business Wire
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.7%Should You Buy? - MarketBeat
VOXX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of VOXX International Corporation Is Fair to Shareholders - Business Wire
Soho House & Co Inc. to Announce Third Quarter 2024 Results on December 19, 2024 - Business Wire
Charles Schwab Investment Management Inc. Buys New Stake in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Charles Schwab Investment Management Inc. Takes Position in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
ENPH Investors Have Opportunity to Lead Enphase Energy, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Flexsteel Industries, Inc. Announces Quarterly Dividend and Authorizes New Share Repurchase Program - Business Wire
CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors - citybiz
Companies Like Rapport Therapeutics (NASDAQ:RAPP) Can Afford To Invest In Growth - Simply Wall St
We're Not Worried About Rapport Therapeutics' (NASDAQ:RAPP) Cash Burn - Yahoo Finance
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):